CORRESP Filing
Bio Green Med Solution, Inc.
Date: July 30, 2025 · CIK: 0001130166 · Accession: 0001641172-25-021612
AI Filing Summary & Sentiment
Reasoning
Referenced dates: July 25, 2025
Letter
VIA EDGAR Attention: Jason Drory Division of Corporation Finance Securities and Exchange Commission Office of Life Sciences Re: Cyclacel Pharmaceuticals, Inc. Registration Statement on Form S-1 Submitted July 24, 2025 CIK No. 0001130166
Dear Ladies and Gentlemen,
On behalf of Cyclacel Pharmaceuticals, Inc. (the "Company"), we are writing to submit the Company's response to the comment issued by the staff of the Division of Corporation Finance of the Securities and Exchange Commission (the "Staff") dated July 25, 2025 (the "Comment Letter"), with respect to the above-referenced registration statement on Form S-1 filed on July 24, 2025 (the "Registration Statement") relating to the registration under the Securities Act of 1933, as amended, of the securities of the Company. Concurrently with this submission, the Company has filed the first amendment to the Registration Statement on Form S-1/A. The response set forth below are based upon information provided to Rimon P.C.
Registration Statement on Form S-1 filed July 24, 2025
General
1. We note your response to prior comment 1 and reissue in part. You do not appear to have revised your registration statement to include the pro forma financial information required by Rule 8-05 of Regulation S-X, as your response indicates. Please revise accordingly, or advise.
Response : We acknowledge the Staff's comment and advise in response that the Company has revised the Registration Statement to include the pro forma financial information required by Rule 8-05 of Regulation S-X.
*****
We respectfully request the Staff's assistance in completing the review of the Registration Statement. If you have any additional questions regarding any of our responses or the revised Registration Statement, please do not hesitate to contact Debbie Klis on (202) 935-3390 of Rimon P.C.
Kindest regards,
/s/ Debbie A. Klis
Rimon P.C.
cc: Datuk Dr. Doris Wong, CEO
Show Raw Text
CORRESP 1 filename1.htm 1050 Connecticut Ave NW, Suite 500 Washington, D.C. 20036 July 30, 2025 VIA EDGAR Attention: Jason Drory Laura Crotty Division of Corporation Finance Securities and Exchange Commission Office of Life Sciences 100 F Street, NE Washington DC 20549 Re: Cyclacel Pharmaceuticals, Inc. Registration Statement on Form S-1 Submitted July 24, 2025 CIK No. 0001130166 Dear Ladies and Gentlemen, On behalf of Cyclacel Pharmaceuticals, Inc. (the "Company"), we are writing to submit the Company's response to the comment issued by the staff of the Division of Corporation Finance of the Securities and Exchange Commission (the "Staff") dated July 25, 2025 (the "Comment Letter"), with respect to the above-referenced registration statement on Form S-1 filed on July 24, 2025 (the "Registration Statement") relating to the registration under the Securities Act of 1933, as amended, of the securities of the Company. Concurrently with this submission, the Company has filed the first amendment to the Registration Statement on Form S-1/A. The response set forth below are based upon information provided to Rimon P.C. Registration Statement on Form S-1 filed July 24, 2025 General 1. We note your response to prior comment 1 and reissue in part. You do not appear to have revised your registration statement to include the pro forma financial information required by Rule 8-05 of Regulation S-X, as your response indicates. Please revise accordingly, or advise. Response : We acknowledge the Staff's comment and advise in response that the Company has revised the Registration Statement to include the pro forma financial information required by Rule 8-05 of Regulation S-X. ***** We respectfully request the Staff's assistance in completing the review of the Registration Statement. If you have any additional questions regarding any of our responses or the revised Registration Statement, please do not hesitate to contact Debbie Klis on (202) 935-3390 of Rimon P.C. Kindest regards, /s/ Debbie A. Klis Rimon P.C. cc: Datuk Dr. Doris Wong, CEO